Salvage mFOLFOX in BTC After Failure of Gemcitabine
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age : older than 18
Histologically confirmed adenocarcinoma of the biliary tract
Metastatic or unresectable biliary cancer
Prior exposure to gemcitabine chemotherapy for biliary cancer
Eastern Cooperative Oncology Group (ECOG) performance status 0 -2
A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in spiral Computed Tomography (CT) or multidetector CT
Adequate bone marrow, liver, renal function
Pregnancy and breast-feeding.
Other serious illness or medical condition, notably heart or lung failure, active uncontrolled infection (infection requiring antibiotics).
Past or concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix.